JCIA
BCRX icon

Jackson Creek Investment Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jackson Creek Investment Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-36,354
Closed -$276K – 299
2025
Q3 		$276K Sell
36,354
-69
-0.2% -$575 0.08% 268
2025
Q2 		$326K Buy
+36,423
New +$339K 0.09% 289

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jackson Creek Investment Advisors's BCRX Position: Q4 2025 in Review

Jackson Creek Investment Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 36,354 shares — an estimated $276K sold.

Jackson Creek Investment Advisors first reported a position in BCRX in Q2 2025 and held it in 2 quarters. The position peaked at $326K in Q2 2025. 273 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Jackson Creek Investment Advisors reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jackson Creek Investment Advisors sold 36,354 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $276K.
  • Jackson Creek Investment Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Jackson Creek Investment Advisors's BioCryst Pharmaceuticals position peaked at $326K in Q2 2025.
  • 273 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Jackson Creek Investment Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.